News - OBI Pharma 台灣浩鼎

2019.Jan.09

未分類

Corporate

OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference

2018.Nov.21

未分類

Corporate

OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer

2018.Sep.19

未分類

Corporate

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)

2018.Jul.08

未分類

Corporate

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)

2018.Apr.19

未分類

Corporate

OBI Pharma Announces FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors

2018.Jan.17

未分類

Corporate

OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)

2017.Dec.22

未分類

Corporate

OBI Pharma announces participation at the 36th J.P. Morgan Annual Healthcare Conference in San Francisco from January 8-10, 2018.

2017.Oct.30

未分類

Corporate

OBI Pharma announces OBI-3424 results from the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2017.Oct.24

未分類

Corporate

OBI Pharma Announces Presentation on OBI-3424 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2017.Jul.11

未分類

Corporate

Licensing agreement of ThioBridge™ signed with Abzena (AIM: ABZA)

Announcements

Latest announcements

Events

Latest events